Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization.

<h4>Background and aims</h4>Treatment of patients with Barcelona Clinic Liver Cancer Stage B hepatocellular carcinoma (BCLC-B HCC) is controversial. This study compared the long-term survival of patients with BCLC-B HCC who received liver resection (LR) or transarterial chemoembolization...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jian-Hong Zhong, Bang-De Xiang, Wen-Feng Gong, Yang Ke, Qin-Guo Mo, Liang Ma, Xing Liu, Le-Qun Li
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/3b21715d063043b98a7bb3bae3d4eaf3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3b21715d063043b98a7bb3bae3d4eaf3
record_format	dspace
spelling	oai:doaj.org-article:3b21715d063043b98a7bb3bae3d4eaf32021-11-18T07:38:09ZComparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization.1932-620310.1371/journal.pone.0068193https://doaj.org/article/3b21715d063043b98a7bb3bae3d4eaf32013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23874536/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background and aims</h4>Treatment of patients with Barcelona Clinic Liver Cancer Stage B hepatocellular carcinoma (BCLC-B HCC) is controversial. This study compared the long-term survival of patients with BCLC-B HCC who received liver resection (LR) or transarterial chemoembolization (TACE).<h4>Methods</h4>A total of 257 and 135 BCLC-B HCC patients undergoing LR and TACE, respectively, were retrospectively evaluated. Kaplan-Meier method was used for long-term survival analysis. Independent prognostic predictors were determined by the Cox proportional hazards model.<h4>Results</h4>The hospital mortality rate was similar between groups (3.1% vs. 3.7%; P = 0.76). However, the LR group showed a significantly higher postoperative complication rate than the TACE group (28 vs. 18.5%; P = 0.04). At the same time, the LR group showed significantly higher overall survival rates (1 year, 84 vs. 69%; 3 years, 59 vs. 29%; 5 years, 37 vs. 14%; P<0.001). Moreover, similar results were observed in the propensity score model. Three independent prognostic factors were associated with worse overall survival: serum AFP level (≥400 ng/ml), serum ALT level, and TACE.<h4>Conclusions</h4>LR appears to be as safe as TACE for patients with BCLC-B HCC, and it provides better long-term overall survival. However, prospective studies are needed to disclose if LR may be regarded as the preferred treatment for these patients as long as liver function is preserved.Jian-Hong ZhongBang-De XiangWen-Feng GongYang KeQin-Guo MoLiang MaXing LiuLe-Qun LiPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 7, p e68193 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jian-Hong Zhong Bang-De Xiang Wen-Feng Gong Yang Ke Qin-Guo Mo Liang Ma Xing Liu Le-Qun Li Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization.
description	<h4>Background and aims</h4>Treatment of patients with Barcelona Clinic Liver Cancer Stage B hepatocellular carcinoma (BCLC-B HCC) is controversial. This study compared the long-term survival of patients with BCLC-B HCC who received liver resection (LR) or transarterial chemoembolization (TACE).<h4>Methods</h4>A total of 257 and 135 BCLC-B HCC patients undergoing LR and TACE, respectively, were retrospectively evaluated. Kaplan-Meier method was used for long-term survival analysis. Independent prognostic predictors were determined by the Cox proportional hazards model.<h4>Results</h4>The hospital mortality rate was similar between groups (3.1% vs. 3.7%; P = 0.76). However, the LR group showed a significantly higher postoperative complication rate than the TACE group (28 vs. 18.5%; P = 0.04). At the same time, the LR group showed significantly higher overall survival rates (1 year, 84 vs. 69%; 3 years, 59 vs. 29%; 5 years, 37 vs. 14%; P<0.001). Moreover, similar results were observed in the propensity score model. Three independent prognostic factors were associated with worse overall survival: serum AFP level (≥400 ng/ml), serum ALT level, and TACE.<h4>Conclusions</h4>LR appears to be as safe as TACE for patients with BCLC-B HCC, and it provides better long-term overall survival. However, prospective studies are needed to disclose if LR may be regarded as the preferred treatment for these patients as long as liver function is preserved.
format	article
author	Jian-Hong Zhong Bang-De Xiang Wen-Feng Gong Yang Ke Qin-Guo Mo Liang Ma Xing Liu Le-Qun Li
author_facet	Jian-Hong Zhong Bang-De Xiang Wen-Feng Gong Yang Ke Qin-Guo Mo Liang Ma Xing Liu Le-Qun Li
author_sort	Jian-Hong Zhong
title	Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization.
title_short	Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization.
title_full	Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization.
title_fullStr	Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization.
title_full_unstemmed	Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization.
title_sort	comparison of long-term survival of patients with bclc stage b hepatocellular carcinoma after liver resection or transarterial chemoembolization.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/3b21715d063043b98a7bb3bae3d4eaf3
work_keys_str_mv	AT jianhongzhong comparisonoflongtermsurvivalofpatientswithbclcstagebhepatocellularcarcinomaafterliverresectionortransarterialchemoembolization AT bangdexiang comparisonoflongtermsurvivalofpatientswithbclcstagebhepatocellularcarcinomaafterliverresectionortransarterialchemoembolization AT wenfenggong comparisonoflongtermsurvivalofpatientswithbclcstagebhepatocellularcarcinomaafterliverresectionortransarterialchemoembolization AT yangke comparisonoflongtermsurvivalofpatientswithbclcstagebhepatocellularcarcinomaafterliverresectionortransarterialchemoembolization AT qinguomo comparisonoflongtermsurvivalofpatientswithbclcstagebhepatocellularcarcinomaafterliverresectionortransarterialchemoembolization AT liangma comparisonoflongtermsurvivalofpatientswithbclcstagebhepatocellularcarcinomaafterliverresectionortransarterialchemoembolization AT xingliu comparisonoflongtermsurvivalofpatientswithbclcstagebhepatocellularcarcinomaafterliverresectionortransarterialchemoembolization AT lequnli comparisonoflongtermsurvivalofpatientswithbclcstagebhepatocellularcarcinomaafterliverresectionortransarterialchemoembolization
_version_	1718423153501274112

Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization.

Ejemplares similares